NASDAQ : PALI
Palisade Bio, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.19 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 207.38M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 202.15M |
| Enterprise Value | 76.98M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 174.27M |
| Shares Outstanding | 174.27M |
| Shares Change (YoY) | +4,683.09% |
| Shares Change (QoQ) | +0.82% |
| Owned by Insiders (%) | 2.30% |
| Owned by Institutions (%) | 80.93% |
| Float | 135.43M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 404.31 |
| Forward PS | n/a |
| PB Ratio | 1.65 |
| P/TBV Ratio | 1.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 153.96 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 24.26 |
| Quick Ratio | 23.96 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4,418.63 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -51.37% |
| Return on Assets (ROA) | -32.98% |
| Return on Invested Capital (ROIC) | -35.43% |
| Return on Capital Employed (ROCE) | -28.96% |
| Weighted Average Cost of Capital (WACC) | 13.16% |
| Revenue Per Employee | $35,714 |
| Profits Per Employee | -$2.28M |
| Employee Count | 14 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.62 |
| 52-Week Price Change | -45.28% |
| 50-Day Moving Average | 1.65 |
| 200-Day Moving Average | 1.85 |
| Relative Strength Index (RSI) | 30.26 |
| Average Volume (20 Days) | 2,966,712 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 31.75M |
| Short Previous Month | 31.02M |
| Short % of Shares Out | 18.22% |
| Short % of Float | 23.44% |
| Short Ratio (days to cover) | 8.75 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 500,000 |
| Gross Profit | 500,000 |
| Operating Income | -35.35M |
| Pretax Income | -31.94M |
| Net Income | -31.94M |
| EBITDA | -35.35M |
| EBIT | -35.35M |
| Loss Per Share | -$0.20 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 125.17M |
| Total Debt | n/a |
| Net Cash | 125.17M |
| Net Cash Per Share | $0.72 |
| Equity (Book Value) | 121.75M |
| Book Value Per Share | 0.70 |
| Working Capital | 122.01M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -18.19M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 2,500 |
| Net Borrowing | -311,000 |
| Free Cash Flow | -18.19M |
| FCF Per Share | -$0.10 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -7,069.80% |
| Pretax Margin | -6,388.20% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4,683.09% |
| Shareholder Yield | -4,683.09% |
| Earnings Yield | -17.37% |
| FCF Yield | -9.00% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $9.80 |
| Price Target Difference | 744.83% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 8, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 21.8 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |